| |
|
Product Name:
|
P57072
|
|
Manufacturer:
|
BEI Resources
|
|
Taxonomy:
|
Classification: Mitosporic Saccharomycetales; Candida
Species: Candida albicans
Strain/Isolate: P57072
|
|
Additional Information:
|
C. albicans is a eukaryotic, pathogenic obligate aerobe that is responsible for the majority of forms of candidiasis and is responsible for superficial as well as life-threatening systemic infections. It is commonly isolated from the environment and can be a component of the microbial floras of the human oral cavity, gastrointestinal tract or vagina. Several features of C. albicans contribute to its virulence. These include the secretion of hydrolytic enzymes, the ability to adhere to host cells and tissues, phenotypic switching (a phenomena that involves changing several growth and morphological characteristics at the same time) and morphological dimorphism (growth can be yeast-like or mycelial). C. albicans is generally diploid and exhibits considerable natural heterozygosity.4,5,6,7,8,9
|
|
Material Provided:
|
Each vial contains approximately 0.5 mL of yeast culture in 20% glycerol.
Note: If homogeneity is required for your intended use, please purify prior to initiating work.
|
|
Packing/Storage:
|
NR-29435 was packaged aseptically in cryovials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.
|
|
Growth Conditions:
|
Media:
Yeast Mold broth or Emmons Modified Sabouraud broth or equivalent
Yeast Mold agar or Emmons Modified Sabouraud agar or equivalent
Incubation:
Temperature: 25°C to 30°C
Atmosphere: Aerobic
Propagation:
1. Keep vial frozen until ready for use; thaw rapidly in a water bath at 25°C to 30°C. Typically, this takes less than 5 minutes.
2. Immediately after thawing, inoculate an agar plate with approximately 50 µL of thawed culture and/or transfer the entire thawed aliquot into a single tube of broth.
3. Incubate the plate and/or tube at 25°C to 30°C for 2 to 4 days.
|
|
Disclaimers:
|
You are authorized to use this product for research use only. It is not intended for human use. Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org. While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate. This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/ or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products. |
References:
|
1. Soll, D. R., Personal Communication.
2. Lockhart, S.R., et al. “In Candida albicans, White-Opaque Switchers are Homozygous for Mating Type.” Genetics 162 (2002): 737-745. PubMed: 12399384.
3. Pujol, C., et al. “Drug Resistance is not Directly Affected by Mating Type Locus Zygosity in Candida albicans.” Antimicrob. Agents Chemother. 47 (2003): 1207-1212. PubMed: 12654648.
4. Wu, W., et al. “Heterozygosity of Genes on the Sex Chromosome Regulates Candida albicans Virulence.” Mol. Microbiol. 64 (2007): 1587-1604. PubMed: 17555440.
5. Kim, J. and P. Sudbery. “Candida albicans, a Major Human Fungal Pathogen.” J. Microbiol. 49 (2011): 171-177. PubMed: 21538235.
6. Karkowska-Kuleta, J., M. Rapala-Kozik and A. Kozik. “Fungi Pathogenic to Humans: Molecular Bases of Virulence of Candida albicans, Cryptococcus neoformans and Aspergillus fumigatus.” Acta Biochim. Pol. 56 (2009): 211-224. PubMed: 19543556.
7. Niimi, M., R. D. Cannon and B. C. Monk. “Candida albicans Pathogenicity: A Proteomic Perspective.” Electrophoresis 20 (1999): 2299-2308. PubMed: 10493133.
8. Jones, T., et al. “The Diploid Genome Sequence of Candida albicans.” Proc. Natl. Acad. Sci. USA 101 (2004): 7329-7334. PubMed: 15123810.
9. d’Enfert, C., et al. “CandidaDB: A Genome Database for Candida albicans Pathogenomics.” Nucleic Acids Res. 33 (2005): D353-D357. PubMed: 15608215.
|
|
Citation:
|
Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Candida albicans, Strain P57072, NR-29435."
|
|
Biosafety Level:
|
2
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories (BMBL). Current Edition. Washington, DC: U.S. Government Printing Office.
|